Xultophy(R) Offers Greater Blood Sugar and Body Weight Reductions in People With Type 2 Diabetes, Compared to IGlarLixi

PR71369

COPENHAGEN, Denmark, December 4, 2017/PRNewswire=KYODO JBN/ --

    New findings from an indirect comparison between Xultophy(R) and IGlarLixi

published in the Journal of Medical Economics show that treatment with

Xultophy(R) (insulin degludec/liraglutide) provides statistically significant

greater reductions in blood sugar levels and body weight compared with

IGlarLixi (insulin glargine U100/lixisenatide), in people with type 2 diabetes

who struggle to achieve desired blood sugar targets with basal insulin alone.[1]

    "In the absence of a head-to-head trial between Xultophy(R) and IGlarLixi,

the solid methodology of this indirect comparison, where we adjusted for key

differences between study designs and patient populations, allows us to

conclude that Xultophy(R) can deliver greater reductions in the overall blood

sugar levels and weight for people with type 2 diabetes who are uncontrolled on

basal insulin, compared to IGlarLixi," said lead study author Professor Marc

Evans of University Hospital, Llandough in Cardiff, UK. "This analysis is based

on published data from individual clinical trials which involved over 700

adults living with type 2 diabetes."

    This indirect comparison showed that, within the study population, people

with type 2 diabetes uncontrolled on basal insulin achieved a 0.44% greater

reduction of their overall blood sugar levels (HbA1c), and a 1.42 kg greater

weight loss when treated with Xultophy(R) , compared to those treated with

IGlarLixi, at similar doses of insulin. Additionally, the analysis found a

higher likelihood of reaching target blood sugar levels (HbA1c <7%) with

Xultophy(R), compared to IGlarLixi.[1]

    About the analysis

    This analysis was an indirect comparison using published data from phase 3

trials providing evidence for estimating the relative efficacy and safety of

Xultophy(R) versus IGlarLixi in people with type 2 diabetes uncontrolled on

basal insulin. Outcomes of interest were change in HbA1c, body weight, insulin

dose and rate ratio of hypoglycaemia. Xultophy(R) was estimated to provide a

0.44% point reduction in HbA1c compared with IGlarLixi [95%CI: 0.17, 0.71].

Body weight was reduced by 1.42 kg with Xultophy(R), compared to IGlarLixi

[95%CI: 0.35, 2.50].[1]

    The results mentioned above were achieved at similar insulin doses. The

rate of severe or blood glucose-confirmed hypoglycaemia with Xultophy(R) was

approximately half that of IGlarLixi (rate ratio 0.51 [95%CI: 0.29, 0.90]. Rate

ratios for severe or BG-confirmed hypoglycaemia are based on a target of less

than or equal to3.1 mmol/L in the Xultophy(R) trials and less than or equal

to3.3 mmol/L in the IGlarLixi trial). However, using the American Diabetes

Association definition of documented symptomatic hypoglycaemia (SMPG less than

or equal to3.9 mmol/L) the rate was comparable between the two treatments (rate

ratio 1.07 [95%CI: 0.90, 1.28]). Limitations of this indirect comparison

include: differences in study design, patient characteristics and the

definition of hypoglycaemia. [1]

    The article published in the Journal of Medical Economics can be accessed

online at: http://dx.doi.org/10.1080/13696998.2017.1409228.

    About Xultophy[(R)]

    Xultophy(R) is a once-daily single injection fixed-ratio combination of

long-acting insulin degludec and the glucagon-like peptide-1 (GLP-1) receptor

agonist liraglutide in one pen. It is indicated for the treatment of adults

with type 2 diabetes mellitus to improve glycaemic control in combination with

oral glucose-lowering medicinal products when these alone or combined with

basal insulin do not provide adequate glycaemic control. Xultophy(R) is given

once daily by subcutaneous injection. Xultophy(R) can be administered at any

time of the day with or without meals, preferably at the same time of the

day.[2]

    About Novo Nordisk

    Novo Nordisk is a global healthcare company with more than 90 years of

innovation and leadership in diabetes care. This heritage has given us

experience and capabilities that also enable us to help people defeat obesity,

haemophilia, growth disorders and other serious chronic diseases. Headquartered

in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries

and markets its products in more than 165 countries. For more information,

visit novonordisk.com [https://www.novonordisk.com ], Facebook

[http://www.facebook.com/novonordisk ], Twitter

[http://www.twitter.com/novonordisk ], LinkedIn

[http://www.linkedin.com/company/novo-nordisk ], YouTube

[http://www.Youtube.com/novonordisk ]

    Further information    

    Media:

    Katrine Sperling

    +45-4442-6718

    krsp@novonordisk.com

    Åsa Josefsson

    +45-3079-7708

    aajf@novonordisk.com

    Investors:

    Peter Hugreffe Ankersen

    +45-3075-9085

    phak@novonordisk.com

    Hanna Ogren

    +45-3079-8519

    haoe@novonordisk.com

    Anders Mikkelsen

    +45-3079-4461

    armk@novonordisk.com

    Christina Kjaer

    +45-3079-3009

    cnje@novonordisk.com

    Kasper Veje (US)

    +1-609-235-8567

    kpvj@novonordisk.com

     References

    1. Evans M, Billings LK, Håkan-Bloch J, et al. An indirect treatment

comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and

insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes

uncontrolled on basal insulin. Journal of Medical Economics. 2017;Published

online ahead of print.

    2. EMA. Xultophy(R) Summary of Product Characteristics. Available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002647/WC500177657.pdf

. Last accessed: November 2017.

    Source: Novo Nordisk